The primary purpose of this proposal is three-fold: 1) to continue to evaluate the behavioral effects of drugs that act as agonists or antagonists at the NMDA subtype of the glutamate (excitatory neurotransmitter) receptor; 2) to begin to understand more of the behavioral pharmacology of nitric oxide primarily by using nitric oxide synthase inhibitors; and 3) to use newly available drugs that have parenteral activity to study the behavioral pharmacology of the AMPA subtype of the glutamate receptor. With respect to item 1), it has been found that the NMDA receptor contains sites for glycine as well as glutamate, and both of these excitatory amino acids ar necessary to activate this receptor. We have studied the interaction between agonists and antagonists at both these sites extensively in the mouse. The current proposal will extend these interaction studies to the pigeon and the monkey using primarily rates of food-maintained responding and discriminative stimulus effects as assays. With respect to item 2), it has been found that activation of the NMDA receptor results in production of nitric oxide from L-arginine, catalyzed by nitric oxide synthase. Similar effects of nitric oxide synthase inhibitors and PCP have been found in our studies of the discriminative stimulus effects of PCP. Part of the rationale for the proposed studies is to determine how much of the effects of PCP-like drugs and other NMDA antagonists and agonists are through NO formation. With respect to item 3), there has been very little work done on the in vivo effects of AMPA agonists and antagonists, because parenterally active drugs are only recently available. The behavioral effects of these drugs will be evaluated during this grant period. In addition to the effects of a number of EAA agonists and antagonists on rates of responding and their ability to serve as discriminative stimuli, a number of studies of the effects of these drugs on learning and memory in the pigeon are planned. Each of the three areas described above (glycine:glutamate; NO; AMPA) have well-characterized effects on long-term potentiation in the hippocampus, and less well-characterized effects on learning in animals. This is a fascinating and important area that will be explored in depth in this grant period.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA005325-08
Application #
2117569
Study Section
Special Emphasis Panel (SRCD (27))
Project Start
1988-04-01
Project End
1998-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Baron, S P; Woods, J H (1993) Dipsogenic effects of excitatory amino acid agonists in pigeons. J Pharmacol Exp Ther 264:918-21
Bertalmio, A J; Woods, J H (1992) Discriminative stimulus effects of cyclorphan: selective antagonism with naltrexone. Psychopharmacology (Berl) 106:189-94
Hoenicke, E M; Vanecek, S A; Woods, J H (1992) The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther 263:276-84
Lu, Y; France, C P; Woods, J H (1992) Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. J Pharmacol Exp Ther 263:499-504
Walker, E A; Yamamoto, T; Hollingsworth, P J et al. (1991) Discriminative-stimulus effects of quipazine and l-5-hydroxytryptophan in relation to serotonin binding sites in the pigeon. J Pharmacol Exp Ther 259:772-82
France, C P; Moerschbaecher, J M; Woods, J H (1991) MK-801 and related compounds in monkeys: discriminative stimulus effects and effects on a conditional discrimination. J Pharmacol Exp Ther 257:727-34
Yamamoto, T; Walker, E A; Woods, J H (1991) Agonist and antagonist properties of serotonergic compounds in pigeons trained to discriminate either quipazine or L-5-hydroxytryptophan. J Pharmacol Exp Ther 258:999-1007
France, C P; Lu, Y; Woods, J H (1990) Interactions between N-methyl-D-aspartate and CGS 19755 administered intramuscularly and intracerebroventricularly in pigeons. J Pharmacol Exp Ther 255:1271-7
Koek, W; Woods, J H; Colpaert, F C (1990) N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. J Pharmacol Exp Ther 253:1017-25
France, C P; Winger, G D; Woods, J H (1990) Analgesic, anesthetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys. Brain Res 526:355-8

Showing the most recent 10 out of 14 publications